Elsilimomab Explained

Elsilimomab (also known as B-E8) is a mouse monoclonal antibody.[1] B-E8 was developed by Diaclone,[2] a French company which produces many mouse monoclonal antibodies.

It (OPR-003) targets (and blocks) Interleukin-6.[3]

It has undergone a number of early stage clinical trials, e.g. for lymphoma and myeloma.[4]

It was used as a template to develop a high-affinity, antagonist, fully human anti-IL-6 mAb 1339.[4]

Notes and References

  1. Web site: WHO Drug Information . https://web.archive.org/web/20091016222527/http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf . dead . October 16, 2009 . p11:immunoglobulin G1, anti-(human interleukin 6) (mouse monoclonal B-E8 heavy chain), disulfide with mouse monoclonal B-E8 k-chain, dimer .
  2. Web site: Datasheet B-E8 mAb . Diaclone .
  3. News: First Fully Human Anti-IL6 Antibody Under Development . Genetic Engineering & Biotechnology News . Oct 2006 .
  4. Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z, Patel N, Smith ES, Wang W, Prabhala R, Tai YT, Tassone P, Anderson KC, Munshi NC . 6 . A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma . Clinical Cancer Research . 15 . 23 . 7144–52 . December 2009 . 19934301 . 2787636 . 10.1158/1078-0432.CCR-09-1483 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Elsilimomab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.